

Supplemental Information

**Intracranial delivery of AAV9 gene therapy
partially prevents retinal degeneration
and visual deficits in CLN6-Batten disease mice**

Katherine A. White, Hemanth R. Nelvagal, Timothy A. Poole, Bin Lu, Tyler B. Johnson, Samantha Davis, Melissa A. Pratt, Jon Brudvig, Ana B. Assis, Shibi Likhite, Kathrin Meyer, Brian K. Kaspar, Jonathan D. Cooper, Shaomei Wang, and Jill M. Weimer

WT




hCLN6/DAPI*Cln6^{nclf}**Cln6^{nclf}* + scAAV9

Figure S1. Wildtype and *Cln6^{nclf}* control show limited *hCLN6* RNAscope expression, while AAV9 treated *Cln6^{nclf}* animal shows robust *hCLN6* expression (purple). Shown in brain tissue.




Figure S2. Representative whole-mount image of scAAV9 treated animal shows primarily central retinal expression when immunolabeled with an anti-hCLN6 antibody (red).